Quigley moves Elizabethtown, Pa. operations to Lebanon, Pa.
DOYLESTOWN, Pa. The Quigley Corporation on Tuesday announced plans to consolidate its Pennsylvania-based manufacturing operations by closing its manufacturing facility in Elizabethtown, Pa. and move those operations to its Lebanon, Pa. facility.
“We anticipate the consolidation of manufacturing capabilities will benefit our cost structure as we reduce costs associated with having two facilities particularly in light of current difficult economic conditions,” stated Guy Quigley, chairman, president and CEO of Quigley.
The Elizabethtown facility primarily produced hard candy products whose profitability in recent times has been adversely affected by increased raw material costs and low-cost foreign sourced products, the company stated. The Quigley Corporation plans to
conclude the closure of the Elizabethtown facility in the coming months with the fulfillment of customer orders, followed by the disposal of location assets.
The Quigley Corporation’s manufacturing facility in Lebanon will continue to produce and ship its COLD-EEZE cold remedy products, as well as the KIDS-EEZE soft chew chest relief OTC expectorant, and Organix Cough and Sore Throat Drops.
Matrixx considering partnership with other OTC companies to release Zicare and Xcid
SCOTTSDALE, Ariz. Matrixx Initiatives is exploring partnering with other over-the-counter companies on the national roll out of its Zicare oral care product and Xcid antacid.
“We continue to explore the possibility of partnering with other parties on both of those projects,,” Bill Hemelt, Matrixx acting president, CFO and COO, told analysts last week. “As we’ve said before, we don’t want to move forward on them by ourselves because of the significant risks associated with that,” he said. “Xcid was a disappointment. … We did roll it out on a limited basis this past year, but it did not meet our expectations. Not because it’s a bad product, it just simply will require greater investment to take that nationally. So we are exploring partnership possibilities for both of those projects.”
Both products are “market ready,” Hemelt said, replete with consumer research and product research.
Zicare, when used in conjunction with a daily oral routine, helps dissolve up to 30% of visible tartar that has already formed and helps inhibit future tartar formation above the gumline, according to the product web site. Zicare is a gel that is applied at the gumline and between the teeth after brushing and before bed.
Xcid is an antacid featuring a unique delivery form — a creamy pudding-like gel available in three flavors: strawberry, orange and chocolate.
Following salmonella outbreak, Obama calls for review of FDA
WASHINGTON The spate of peanut butter recalls associated with salmonella contamination has prompted President Barack Obama to call for a “complete review” of the Food and Drug Administration for failing to detect the contamination before sickening more than 500 people in an interview with TODAY co-host Matt Lauer over the weekend, which aired Monday.
Over the course of the interview, Obama suggested that the comprehensive peanut butter recall was only the latest incident to highlight misgivings about the agency. “The FDA has not been able to catch some of these things as quickly as I expect them to catch,” he said during the interview.